2n35
Fusion to a Highly Stable Consensus Albumin Binding Domain Allows for Tunable PharmacokineticsFusion to a Highly Stable Consensus Albumin Binding Domain Allows for Tunable Pharmacokinetics
Structural highlights
Publication Abstract from PubMedA number of classes of proteins have been engineered for high stability using consensus sequence design methods. Here we describe the engineering of a novel albumin binding domain (ABD) three-helix bundle protein. The resulting engineered ABD molecule, called ABDCon, is expressed at high levels in the soluble fraction of Escherichia coli and is highly stable, with a melting temperature of 81.5 degrees C. ABDCon binds human, monkey and mouse serum albumins with affinity as high as 61 pM. The solution structure of ABDCon is consistent with the three-helix bundle design and epitope mapping studies enabled a precise definition of the albumin binding interface. Fusion of a 10 kDa scaffold protein to ABDCon results in a long terminal half-life of 60 h in mice and 182 h in cynomolgus monkeys. To explore the link between albumin affinity and in vivo exposure, mutations were designed at the albumin binding interface of ABDCon yielding variants that span an 11 000-fold range in affinity. The PK properties of five such variants were determined in mice in order to demonstrate the tunable nature of serum half-life, exposure and clearance with variations in albumin binding affinity. Fusion to a highly stable consensus albumin binding domain allows for tunable pharmacokinetics.,Jacobs SA, Gibbs AC, Conk M, Yi F, Maguire D, Kane C, O'Neil KT Protein Eng Des Sel. 2015 Aug 13. pii: gzv040. PMID:26275855[1] From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine. References
|
| ||||||||||||||||